Trial Condition(s):

Neovascular Glaucoma

Study to learn more about safety of aflibercept injection in Japanese patients with neovascular glaucoma (NVG)

Bayer Identifier:

21220

ClinicalTrials.gov Identifier:

NCT04519619

EudraCT Number:

Not Available

Recruiting

Trial Purpose

This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment.

The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients will be followed for a time period of 6 months from start of Eylea treatment or until it is no longer possible (e.g. lost to follow-up). In total, 480 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visit and final visit, either by routine clinical visits (as per investigators routine practice).

Inclusion Criteria
- Diagnosis of NVG
- Patients who have received IVT-AFL treatment according to Japanese labeling.
Exclusion Criteria
- Patients who are contraindicated based on approved label
- Diagnosis of other indication

Trial Summary

Enrollment Goal
480
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Many locations

Many locations, Japan

Status
Recruiting
 

Trial Design